AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Real-time Estimate Cboe Europe 03:32:14 2024-07-25 am EDT 5-day change 1st Jan Change
11,950.00 GBX -2.16% Intraday chart for AstraZeneca PLC -0.63% +13.68%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Astra ups outlook; Unilever and Lloyds back view AN
AstraZeneca Raises Guidance After Revenue, Earnings Beat Market Expectations DJ
AstraZeneca Posts Higher H1 Attributable Profit, Revenue MT
Sanofi lifts 2024 profit forecast on strength in Dupixent, new drugs RE
AstraZeneca lifts full-year outlook on upbeat demand for therapies RE
MORNING BID EUROPE-Stock rout spreads beyond tech RE
AstraZeneca Secures Global License for Pinetree's Novel Cancer Candidate MT
Precigen, Inc. Announces the Appointment of Phil Tennant as Chief Commercial Officer CI
Astrazeneca plc Announces Voydeya Approved in Canada as Add-On Therapy to Ravulizumab or Eculizumab for Adults with the Rare Disease PNH Who Have Residual Hemolytic Anemia Due to Extravascular Hemolysis CI
ASTRAZENECA : Receives a Buy rating from JP Morgan ZD
Drug giants eye China for deals despite growing Sino-US tensions RE
AstraZeneca's Capivasertib Gets UK Marketing Authorization for Advanced Breast Cancer Treatment MT
EU court criticizes Commission over handling of COVID vaccine contracts RE
Huma Therapeutics Limited announced that it has received $80 million in funding from Hitachi Ventures GmbH, HAT SGR S.p.A., AstraZeneca PLC, Leaps by Bayer CI
Global markets live: Airbus, Burberry, AT&T, Boeing, Vinfast... Our Logo
AstraZeneca: acquisition of Amolyt Pharma finalized CF
AstraZeneca Closes $1.05 Billion Amolyt Pharma Acquisition MT
AstraZeneca PLC completed the acquisition of Amolyt Pharma SAS for $1.05 billion. CI
Instil Bio Shares Surge Following Rental Agreement with AstraZeneca DJ
Sector Update: Health Care Stocks Mixed Premarket Friday MT
Instil Bio Signs Lease With AstraZeneca Pharmaceuticals at California Facility; Shares Rise After Hours MT
ASTRAZENECA : Deutsche Bank reiterates its Neutral rating ZD
Barclays raises Kerry, cuts Hunting, Wood Group AN
ASTRAZENECA : JP Morgan reaffirms its Buy rating ZD
AstraZeneca's Tagrisso Approved by EU as First-Line Treatment for Non-Small Cell Lung Cancer MT
Chart AstraZeneca PLC
More charts
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Employees
89,900
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157.83USD
Average target price
177.79USD
Spread / Average Target
+12.65%
Consensus
  1. Stock Market
  2. Equities
  3. AZN Stock
  4. News AstraZeneca PLC
  5. AstraZeneca Gains US FDA Approval for Endometrial Cancer Treatment